Table 2 Community microfilarial (mf) prevalence and Ov16 seroprevalence in the nine study communities at the study times of November 2020, and June–August 2021
Prevalence of mf, % (n + ve/N examined) [95% CI] | Prevalence of Ov16 antibodies, % (n + ve/N examined) [95% CI] | ||
|---|---|---|---|
All participants Nov 2020 | All participants Aug 2021 | All participants June 2021 | |
Tain District | |||
Abekwai 2 | 4.6% (3/66) [1.6–12.5%] | 11.9% (5/42) [5.2–25.0%] | 16.7% (5/30) [7.3–33.6%] |
Abekwai 3 | 11.0% (8/73) [5.7–20.2%] | 4.0% (4/100) [1.6–9.8%%] | 31.7% (19/60) [21.3–44.2%] |
Attakrom | 10.4% (5/48) [4.5–22.2%] | 20.7% (6/29) [9.9–38.4%] | 22.0% (9/41) [12.0–36.7%] |
Kokomba | NA | 10.0% (4/40) [4.0–23.1%] | 42.5% (17/40) [28.5–57.8%] |
Total Tain | 8.6% (16/187) [5.3–13.5%] | 9.0% (19/211) [5.8–13.6%] | 29.2% (50/171) [22.9–36.5%] |
Wenchi Municipality | |||
Blibor | NA | 19.5% (8/41) [10.2–34.0%] | 10.6% (5/47) [4.6–22.6%] |
Johnykrom | 18.3% (21/115) [12.3–26.3%] | 7.1% (1/14) [1.3–31.5%] | 13.9% (5/36) [6.1–28.7%] |
Subinso 1 | 16.2% (16/99) [10.2–24.7%] | 8.9% (4/45) [3.5–20.7%] | NA |
Subinso 2 | 2.4% (4/164) [1.0–6.1%] | 7.2% (5/69) [3.1–15.9%] | NA |
Kwanware | 12.3% (9/73) [6.6–21.8%] | 11.4% (4/35) [4.5–26.0%] | 11.4% (4/35) [4.5–26.0%] |
Total Wenchi | 11.1% (50/451) [8.5–14.3%] | 10.8% (22/204) [7.2–15.8%] | 11.9% (14/118) [7.2–18.9%] |
Total | 10.3% (66/638) [8.2–13.0%] | 9.9% (41/415) [7.4–13.1%] | 22.2% (64/289) [17.7–27.3%] |